Skip to main content
TipRanks
Go Ultimate75% OFF

Lifeward (LFWD) AI Stock Analysis

845 Followers
LFWD

Lifeward

(NASDAQ:LFWD)

Select Model
Rating:41Neutral
Price Target:$3.00â–²(1.69% Upside)
Action:reiterated
Date:11/18/26

LFWD scores low primarily due to very weak financial performance (sharp net losses, negative cash flow, and declining TTM revenue) and poor technicals (price well below all key moving averages with bearish momentum). Valuation offers limited support because losses drive a negative P/E and there is no dividend yield. Corporate events are slightly supportive (new CFO and strategic messaging) but are not large enough to change the overall risk-heavy picture.

Positive Factors
Manageable LeverageLow absolute debt and improving debt-to-equity provide more financial flexibility than the company’s losses alone would suggest. Manageable leverage reduces interest and refinancing pressure, leaving greater scope to direct future resources toward commercialization, product development, and operational stabilization.
Negative Factors
Severe Profitability PressureLosses are extremely large relative to revenue, indicating that the current operating model has not yet achieved sufficient scale or cost discipline. Persistent negative earnings can weaken equity, constrain investment capacity, and make it harder to fund product development without additional financing.

Lifeward (LFWD) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%LFWD-57.80%SPY+8.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$4.75M
Dividend Yield
―
Average Volume (3M)
12.18K
Price to Earnings (P/E)
-0.2
Beta (1Y)
1.00
Revenue Growth
-14.05%
EPS Growth
55.98%
Country
US
Employees
81
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Lifeward Business Overview & Revenue Model

Company Description

Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with...

How the Company Makes Money

Lifeward makes money primarily by selling and supporting medical devices and related mobility products. A core revenue stream is the sale of ReWalk exoskeleton systems to individual users and/or to institutional customers such as rehabilitation cente...

Lifeward Earnings Call Summary

Earnings Call Date:May 15, 2026(Q1-2026)|% Change Since:-55.27%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentNeutral

Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.

Positive Updates

Strategic Acquisition of Oratech
Completed equity-based acquisition of Oratech, gaining a protein oral delivery platform (including ORMD-0801 oral insulin expected to start Phase II). Transaction described as capital-efficient with minimal near-term operational burden and no material increase in operating expenses.

Negative Updates

Quarterly Revenue Decline
Total revenue for Q1 2026 was $3.9 million vs. $5.0 million in Q1 2025, a decline of approximately 22%, primarily due to reduced AlterG shipments from temporary supply chain and working capital constraints.

Company Guidance

Management did not raise formal 2026 guidance but reiterated they expect full‑year revenue to be similar to 2025, with the Q1 shortfall ($3.9M vs. $5.0M in Q1‑2025) to be largely made up across Q2–Q3 as AlterG backlog ships (potentially resolved by Q3); they highlighted ReWalk revenue up 11% YoY to $1.6M, gross margin down to 34.2% from 42.2% (~800 bps, 75–85% due to FX and tariffs and the rest from lower absorption), total operating expenses of $11.7M (including a ~$4.9M one‑time noncash R&D charge), adjusted Opex down 12% to $5.9M (from $6.8M), GAAP operating loss of $10.3M and unchanged adjusted operating loss of $4.6M, cash used in operations down 33% to $3.7M, and liquidity improved to $11.4M unrestricted cash (vs. $2.2M at YE‑2025) after a $10M convertible financing and ~ $6.5M cash from the Oratech acquisition, positioning the company for operational stabilization and a clearer path to profitability into late 2026/2027.

Lifeward Financial Statement Overview

Summary

Overall financials are weak, led by declining TTM revenue (~-3.5%) and extremely negative profitability (net loss ~$32.7M on ~$21.1M revenue; net margin ~-155%). Cash flow is a major concern with materially negative operating cash flow (~-$19.6M) and negative free cash flow, indicating ongoing cash burn. The main offset is relatively low debt (~$2.5M) and moderate debt-to-equity (~0.34x), but persistent losses are pressuring equity and financial flexibility.

Income Statement

18Very Negative

Balance Sheet

46Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue21.05M22.03M25.66M13.85M5.51M5.97M
Gross Profit6.63M8.43M8.22M4.45M1.91M2.90M
EBITDA-25.80M-19.34M-24.93M-20.28M-18.90M-12.39M
Net Income-32.71M-19.91M-28.94M-22.13M-19.57M-12.74M
Balance Sheet
Total Assets30.52M22.90M30.49M63.19M74.24M94.75M
Cash, Cash Equivalents and Short-Term Investments4.55M2.17M6.94M28.08M67.90M88.34M
Total Debt9.61M4.39M880.00K1.90M897.00K1.06M
Total Liabilities23.25M14.49M11.64M16.68M6.07M5.37M
Stockholders Equity7.27M8.41M18.85M46.51M68.17M89.38M
Cash Flow
Free Cash Flow-19.63M-16.83M-21.72M-20.75M-17.92M-11.52M
Operating Cash Flow-19.62M-16.83M-21.72M-20.67M-17.89M-11.47M
Investing Cash Flow-39.00K-16.00K0-18.15M-25.00K-47.00K
Financing Cash Flow22.28M12.20M0-992.00K-2.50M79.51M

Lifeward Technical Analysis

Technical Analysis SentimentNegative
Last Price2.95

Price Trends

50DMA6.01Negative
100DMA6.76Negative
200DMA6.76Negative

Market Momentum

MACD-0.75Positive
RSI19.19Positive
STOCH2.80Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFWD, the sentiment is Negative. The current price of 2.95 is below the 20-day moving average (MA) of 5.26, below the 50-day MA of 6.01, and below the 200-day MA of 6.76, indicating a bearish trend. The MACD of -0.75 indicates Positive momentum. The RSI at 19.19 is Positive, neither overbought nor oversold. The STOCH value of 2.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFWD.

Lifeward Risk Analysis

Lifeward disclosed 49 risk factors in its most recent earnings report. Lifeward reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Oramed has significant influence over our Company, and its interests may differ from those of our other shareholders.Q3, 2026
2.Our development and use of artificial intelligence ("AI")-enabled technologies may subject us to additional risks and uncertainties.Q3, 2026
3.A regulatory classification matter could affect our ability to market certain AlterG products in the European Union.Q3, 2026

Lifeward Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

LFWD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NSPRNSPR51Neutral$33.59M-1.39-93.52%―35.75%29.98%
NMTCNMTC49Neutral$6.15M-0.74-126.45%―-1.67%7.34%
CTSOCTSO47Neutral$16.17M-0.96-1339.98%―9.04%-44.94%
TELATELA44Neutral$32.84M-0.98425.91%―1.46%15.79%
LFWDLFWD41Neutral$8.37M-0.19-382.80%―-14.05%55.98%
IRIXIRIX40Underperform$8.30M-2.41-84.80%―-2.77%36.12%

* Healthcare Sector Average

Performance Comparison

-50%0%50%LFWDIRIXNSPRCTSONMTCTELADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
LFWD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
LFWDLifeward Ltd.2.95-4.02-57.69%
IRIXIridex0.47-0.45-49.35%
NSPRInspireMD Inc0.62-1.34-68.37%
CTSOCytosorbents Corp5.13-11.45-69.06%
NMTCNeuroone Medical Technologies Corporation0.67-3.31-83.09%
TELATela Bio, Inc.0.73-0.41-36.32%

Lifeward Corporate Events

Executive/Board ChangesShareholder Meetings

Lifeward Shareholders Approve Key Proposals, Reject Compensation Policy

Neutral
Nov 5, 2026

At the October 30, 2026 annual and extraordinary general meeting, Lifeward shareholders representing 71.7% of outstanding ordinary shares constituted a quorum. Shareholders approved the re-election of Haggai Zamir and Avi Gabay, the election and comp...

Executive/Board ChangesShareholder Meetings

Lifeward Appoints New Chief Financial Officer

Positive
Oct 27, 2026

On October 26, 2026, Lifeward Ltd.’s board appointed seasoned finance executive Ronen Tsimerman as chief financial officer, principal financial officer and principal accounting officer, effective November 1, 2026. Tsimerman brings extensive experienc...

Executive/Board Changes

Lifeward Continues CFO Search After Candidate Withdraws

Negative
Oct 8, 2026

Lifeward Ltd. had previously announced that Rami Aviram would become its chief financial officer, principal financial officer and principal accounting officer effective November 1, 2026, but on October 4, 2026 he informed the company he would not joi...

Executive/Board Changes

Lifeward Announces Interim CFO Leadership Transition Phase

Neutral
Oct 1, 2026

On September 30, 2026, Lifeward Ltd. completed the previously announced transition of its Chief Financial Officer role with the departure of Almog Adar as CFO, principal financial officer, and principal accounting officer. Effective October 1, 2026,...

Regulatory Filings and ComplianceShareholder Meetings

Lifeward Sets Timeline for 2026 Shareholder Meeting

Neutral
Sep 15, 2026

Lifeward Ltd. has scheduled its 2026 Annual and Extraordinary General Meeting of Shareholders for October 30, 2026, marking a meeting date set more than 30 days after the anniversary of its 2025 annual general meeting. The board has outlined the time...

Business Operations and StrategyFinancial Disclosures

Lifeward Highlights Growth Strategy in New Investor Presentation

Positive
Sep 8, 2026

On September 8, 2026, Lifeward posted a new investor presentation outlining its investment thesis and growth strategy, underscoring a commercial platform built around robotics, AI and reimbursement to restore motion and independence for patients with...

Business Operations and StrategyExecutive/Board Changes

Lifeward Announces Major CEO and CFO Leadership Changes

Neutral
Aug 31, 2026

Lifeward Ltd. underwent significant leadership changes on August 31, 2026, when President and Chief Executive Officer Mark Grant departed from his executive roles and board seat under a separation agreement that ended future equity vesting and provid...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026